{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:18:50Z","timestamp":1794539930111,"version":"4.9.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Population-based data comparing the outcomes of patients with transformed follicular lymphoma (t-FL) and de novo diffuse large B-cell lymphoma (DLBCL) are lacking. The objective of this study was to compare the survival of patients with t-FL and de novo DLBCL diagnosed in the United States between 2010\u20132018. We hypothesized that patients with t-FL would have an inferior survival compared to patients with de novo DLBCL. The study outcomes were relative survival (RS), overall survival (OS), and lymphoma-specific survival (LSS) compared between t-FL and de novo DLBCL. Flexible parametric survival models were used to estimate the study outcomes. There were 569 cases of t-FL and 44,706 cases of de novo DLBCL. Patients with t-FL had an estimated 5-year RS of 54% [95% confidence interval (CI), 49\u201359%) compared to 67% (95% CI, 66\u201367%) for those with de novo DLBCL (adjusted hazard ratio, 1.29; 95% CI, 1.11\u20131.50; <jats:italic>P<\/jats:italic>\u2009=\u20090.001). The corresponding 5-year OS estimates were 49% (95% CI, 44\u201353%) and 57% (95% CI, 57\u201358%), respectively (adjusted hazard ratio, 1.23; 95% CI, 1.07\u20131.42; <jats:italic>P<\/jats:italic>\u2009=\u20090.004). The corresponding 5-year LSS estimates were 54% (95% CI, 50\u201359%) and 66% (95% CI, 65\u201366%), respectively (adjusted hazard ratio, 1.34; 95% CI, 1.15\u20131.56; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). This population-based registry analysis shows that patients with t-FL continue to have an inferior survival in the modern era and should be prioritized for enrollment in clinical trials.<\/jats:p>","DOI":"10.1186\/s40364-023-00525-1","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T04:01:50Z","timestamp":1695787310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study"],"prefix":"10.1186","volume":"11","author":[{"given":"John L.","family":"Vaughn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"1","key":"525_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","volume":"9","author":"JJ Shuster","year":"1991","unstructured":"Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9(1):191\u20132.","journal-title":"J Clin Oncol"},{"issue":"15","key":"525_CR2","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175\u201397.","journal-title":"Stat Med"},{"key":"525_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987. p. 258 xxix."},{"issue":"9","key":"525_CR4","doi-asserted-by":"publisher","first-page":"e1660","DOI":"10.1002\/onco.13846","volume":"26","author":"S Desai","year":"2021","unstructured":"Desai S, Chaturvedi M, Hameed R, Baez-Sosa V, Shenoy AG. Single-center analysis of characteristics and outcomes of de novo, concurrent, and transformed diffuse large B-Cell Lymphoma. Oncologist. 2021;26(9):e1660\u20133.","journal-title":"Oncologist"},{"issue":"6","key":"525_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.medcli.2016.09.050","volume":"148","author":"M Sorigue","year":"2017","unstructured":"Sorigue M, Garcia O, Baptista MJ, Sancho JM, Tapia G, Mate JL, et al. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy. Med Clin (Barc). 2017;148(6):243\u20139.","journal-title":"Med Clin (Barc)"},{"issue":"6","key":"525_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00277-013-1991-y","volume":"93","author":"HR Guirguis","year":"2014","unstructured":"Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, et al. Survival of patients with transformed lymphoma in the rituximab era. Ann Hematol. 2014;93(6):1007\u201314.","journal-title":"Ann Hematol"},{"issue":"13","key":"525_CR7","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1080\/10428194.2019.1622099","volume":"60","author":"A Behdad","year":"2019","unstructured":"Behdad A, Boddy CS, Fought AJ, Taxter T, Falkiewicz MK, Ayers E, et al. Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. Leuk Lymphoma. 2019;60(13):3266\u201371.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"525_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126(7):851\u20137.","journal-title":"Blood"},{"issue":"32","key":"525_CR9","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(32):5165\u20139.","journal-title":"J Clin Oncol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-023-00525-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-023-00525-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-023-00525-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T20:11:05Z","timestamp":1700511065000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-023-00525-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1186\/s40364-023-00525-1","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. This study was exempt from Institutional Board Review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}